Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma (SSAT042)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01330342 |
Recruitment Status
: Unknown
Verified June 2012 by St Stephens Aids Trust.
Recruitment status was: Recruiting
First Posted
: April 6, 2011
Last Update Posted
: June 11, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV Lymphoma |
The study team will take two or three tubes of blood on three occasions during the course of chemotherapy. The total amount of blood required for this research project is 64mL (approximately 4 tablespoons).
This will allow better understanding of the changes that take place in the blood and the HIV virus itself. It is hoped that this will provide new insights that may aid the understanding and treatment of HIV patients with lymphoma.
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Observational Model: | Case Control |
Official Title: | Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma |
Study Start Date : | May 2011 |
Estimated Primary Completion Date : | May 2014 |
Estimated Study Completion Date : | May 2014 |
Group/Cohort |
---|
HIV patients without lymphoma
HIV-infected subjects on cART without a diagnosis of lymphoma
|
HIV patients with lymphoma
HIV seropositive individuals with lymphoma
|
- Development of multi-drug resistance (in terms of expression of transmembrane transporters and their transcriptional regulators) in HIV-infected patients with lymphoma. [ Time Frame: 3 years ]
- Development of mutations in the HIV genome that may confer resistance to future treatment for HIV. [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements.
- Documented HIV-1 infection.
- Diagnosis of lymphoma (with the exclusion of the five subjects that will be controls).
- On cART or about to start cART as part of clinical routine care before the initiation of chemotherapy.
Exclusion Criteria:
- Receiving anti-tuberculosis treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01330342
Contact: Marta Boffito, Dr | 020 3315 6507 | marta.boffito@chelwest.nhs.uk |
United Kingdom | |
St Stephen's Centre | Recruiting |
London, United Kingdom, SW10 9NH | |
Contact: Marta Boffito, Dr marta.boffito@chelwest.nhs.uk | |
Principal Investigator: Marta Boffito, Dr |
Principal Investigator: | Marta Boffito, Dr | St Stephen's AIDS Trust |
Responsible Party: | St Stephens Aids Trust |
ClinicalTrials.gov Identifier: | NCT01330342 History of Changes |
Other Study ID Numbers: |
SSAT 042 |
First Posted: | April 6, 2011 Key Record Dates |
Last Update Posted: | June 11, 2012 |
Last Verified: | June 2012 |
Additional relevant MeSH terms:
Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |